Skip to content

Study · Animal study (in vivo) · mouse · 2018

11 results

Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.

Huang B, Jiang J, Luo B, Zhu W, Liu Y, Wang Z, Zhang Z

Journal of cellular and molecular medicine23 Mar 2018Cited by 21 (Europe PMC)

PMID29570934 (opens in a new tab)PMCIDPMC6010693 (opens in a new tab)DOI10.1111/jcmm.13608 (opens in a new tab)PepBankPUB-29570934
Download PDFPubMedAsk about this study
Jump to 11 results

Summary

Systemic lupus erythematosus (SLE) is an autoimmune disease, which results in various organ pathologies. However, current treatment towards SLE is suboptimal. Erythropoietin (EPO) has been shown to promote SLE recovery, but clinical application can be limited by its haematopoiesis-stimulating effects. EPO-derived helix-B peptide (ARA290) is non-erythrogenic but has been reported to retain the anti-inflammatory and tissue-protective functions of EPO. Therefore, here we investigated the effects and potential mechanisms of ARA290 on SLE. The administration of ARA290 to pristane-induced SLE and MRL/lpr mice significantly suppressed the level of serum antinuclear autoantibodies (ANAs) and anti-dsDNA autoantibodies, reduced the deposition of IgG and C3, and ameliorated the nephritis symptoms. Moreover, the serum concentrations of inflammatory cytokine IL-6, MCP-1 and TNF-α in SLE mice were reduced by ARA290. Further, ARA290 decreased the number of apoptotic cells in kidney. In vitro experiment revealed that ARA290 inhibited the inflammatory activation of macrophages and promoted the phagocytotic function of macrophages to apoptotic cells. Finally, ARA290 did not induce haematopoiesis during treatment. In conclusion, ARA290 ameliorated SLE, which at least could be partly due to its anti-inflammatory and apoptotic cell clearance promoting effects, without stimulating haematopoiesis, suggesting that ARA290 could be a hopeful candidate for SLE treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pristane-induced SLE and MRL/lpr mice, ARA290 significantly suppressed serum antinuclear autoantibody levels.

    In plain wordsIn mice with lupus, ARA290 lowered blood levels of antibodies that attack the body's own cell nuclei.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseSerum antinuclear autoantibodies (ANAs)
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of ARA290 to pristane-induced SLE and MRL/lpr mice significantly suppressed the level of serum antinuclear autoantibodies (ANAs) and anti-dsDNA autoantibodies
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pristane-induced SLE and MRL/lpr mice, ARA290 significantly suppressed serum anti-dsDNA autoantibody levels.

    In plain wordsIn mice with lupus, ARA290 lowered blood levels of antibodies against the body's own DNA.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseSerum anti-dsDNA autoantibodies
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of ARA290 to pristane-induced SLE and MRL/lpr mice significantly suppressed the level of serum antinuclear autoantibodies (ANAs) and anti-dsDNA autoantibodies
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pristane-induced SLE and MRL/lpr mice, ARA290 reduced the deposition of IgG and C3.

    In plain wordsIn mice with lupus, ARA290 reduced the build-up of immune proteins IgG and C3.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseKidney IgG and C3 deposition
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    reduced the deposition of IgG and C3
    1 context sentence
    Summary · context
    The administration of ARA290 to pristane-induced SLE and MRL/lpr mice
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In pristane-induced SLE and MRL/lpr mice, ARA290 ameliorated the nephritis symptoms.

    In plain wordsIn mice with lupus, ARA290 eased kidney inflammation symptoms.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNephritis symptoms
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ameliorated the nephritis symptoms.
    1 context sentence
    Summary · context
    The administration of ARA290 to pristane-induced SLE and MRL/lpr mice
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In SLE mice, ARA290 reduced serum concentrations of IL-6.

    In plain wordsIn mice with lupus, ARA290 lowered blood levels of the inflammatory signal IL-6.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseSerum IL-6
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, the serum concentrations of inflammatory cytokine IL-6, MCP-1 and TNF-α in SLE mice were reduced by ARA290.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In SLE mice, ARA290 reduced serum concentrations of MCP-1.

    In plain wordsIn mice with lupus, ARA290 lowered blood levels of the inflammatory signal MCP-1.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseSerum MCP-1
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, the serum concentrations of inflammatory cytokine IL-6, MCP-1 and TNF-α in SLE mice were reduced by ARA290.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In SLE mice, ARA290 reduced serum concentrations of TNF-α.

    In plain wordsIn mice with lupus, ARA290 lowered blood levels of the inflammatory signal TNF-α.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseSerum TNF-α
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, the serum concentrations of inflammatory cytokine IL-6, MCP-1 and TNF-α in SLE mice were reduced by ARA290.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In SLE mice, ARA290 decreased the number of apoptotic cells in the kidney.

    In plain wordsIn mice with lupus, ARA290 reduced the number of dying cells in the kidney.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseApoptotic cells in kidney
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Further, ARA290 decreased the number of apoptotic cells in kidney.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In SLE mice, ARA290 did not induce haematopoiesis during treatment.

    In plain wordsIn mice with lupus, ARA290 did not stimulate blood cell production during treatment.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeHaematopoiesis during treatment
    Study

    mousen: not reported in source

    Pristane-induced SLE mice and MRL/lpr mice
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, ARA290 did not induce haematopoiesis during treatment.
  10. 10LabIn vitro (cells)Mechanism

    In macrophages in vitro, ARA290 inhibited inflammatory activation.

    In plain wordsIn cells in the lab, ARA290 reduced the inflammatory switching-on of macrophages.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseInflammatory activation of macrophages
    Study

    n: not reported in source

    Macrophages in vitro
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ARA290 inhibited the inflammatory activation of macrophages
  11. 11LabIn vitro (cells)Mechanism

    In macrophages in vitro, ARA290 promoted the phagocytotic function of macrophages toward apoptotic cells.

    In plain wordsIn cells in the lab, ARA290 helped macrophages clear dying cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseMacrophage phagocytosis of apoptotic cells
    Study

    n: not reported in source

    Macrophages in vitro
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    promoted the phagocytotic function of macrophages to apoptotic cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.